What is Code Bio?
Founded in 2020, Code Bio is a pioneer in the field of genetic medicine, specifically focusing on the development of novel non-viral gene delivery systems. The company's core technology is designed to overcome the limitations of traditional viral vectors, offering a more flexible and scalable approach to gene therapy. By enabling the treatment of diseases characterized by large gene mutations, Code Bio is carving out a unique niche in the biotech sector. Their platform is engineered to be both titratable and re-dosable, providing clinicians with greater control over therapeutic outcomes and expanding the potential patient population for life-altering genetic interventions.
How much funding has Code Bio raised?
Code Bio has raised a total of $85M across 2 funding rounds:
Angel/Seed
$10M
Series A
$75M
Angel/Seed (2021): $10M with participation from CureDuchenne, JDRF T1D Fund, New Enterprise Associates, 4BIO Capital, Takeda Pharmaceutical, and UPMC
Series A (2022): $75M led by New Enterprise Associates, Northpond Ventures, UPMC, UCB Ventures, 4BIO Capital, Hatteras Venture Partners, JDRF T1D Fund, CureDuchenne Ventures, Amgen Business Development, and Takeda Pharmaceutical Company
Key Investors in Code Bio
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
4BIO Capital
4BIO Capital is a London-based venture capital firm specializing in life sciences investments, with a focus on advanced therapies including gene and cell therapy.
JDRF T1D Fund
The T1D Fund is a scaled venture impact fund dedicated to accelerating treatments, prevention, and cures for the 9 million people living with Type 1 Diabetes.
What's next for Code Bio?
With the recent infusion of capital, Code Bio is set to transition into a critical phase of clinical validation and operational expansion. The strategic focus will likely center on advancing lead candidates through preclinical milestones and preparing for initial human trials. Given the participation of major pharmaceutical players and specialized venture impact funds, the company is well-positioned to leverage external expertise in regulatory strategy and manufacturing scale-up. As the firm matures, the emphasis will shift toward establishing long-term partnerships that can facilitate the commercialization of its gene therapy platform, ultimately aiming to redefine the standard of care for patients suffering from rare and debilitating genetic conditions.
See full Code Bio company page
